Derriford Research Facility 2 3
Total Page:16
File Type:pdf, Size:1020Kb
DERRIFORD RESEARCH FACILITY 2 3 UNIVERSITY OF PLYMOUTH FACULTY OF MEDICINE AND DENTISTRY With three core aims at the heart of everything we do, • Our research output in clinical medicine is ranked top in the UK, with 80% exceptional clinical learning, strong social engagement and of the research classed as ‘internationally excellent’ or ‘world leading* world class research, the Faculty has earned a strong and enviable track record for delivering high-calibre training for • The University of Plymouth Brain Tumour Research Centre of Excellence, a wide range of health professionals. Training more than led by Professor Oliver Hanemann, is one of only four in the UK funded 1,800 students and professionals each year, drives forward by Brain Tumour Research. It is playing a key role in researching new the vision for Plymouth as the ‘First Choice for Health’ in the South West. treatments for brain tumours, the biggest cancer killer of children and adults under the age of 40, and tumours of the nervous system Through our graduates and research we celebrate our vision. In addition, we see this recognised through various • The significance of our cross-discipline approach in Parkinson’s disease accolades and privileges. We enjoy ‘top three’ national is recognised through the appointment of Dr Camille Carroll as National status for preparedness for both newly qualified doctors and Institute for Health Research (NIHR) Clinical Research Network (CRN) their clinical supervisors (General Medical Council national Training Survey), and for our dental school (The Guardian National Specialty Lead for Neurodegeneration. There are 127,000 University Guide 2018), whilst our dynamic and rapidly people with Parkinson’s in the UK with one more person diagnosed expanding research operation and reputation continues to every hour shine a spotlight on just how much this comparatively young Faculty is achieving. “At Plymouth we train in the specialities that pretty much reflect the whole workforce of the NHS, and our education mission is underpinned by research. In both education and research we are recognised for quality and achievement, but we cannot afford to stand still. We are committed to finding the solutions to some of the biggest medical challenges.” *Research Excellence Framework (REF) 2014 Professor Rob Sneyd, Dean, Faculty of Medicine and Dentistry 4 5 “This thriving environment looks set to flourish with the opening of Derriford Research Facility headquarters, which INSTITUTE OF TRANSLATIONAL AND provides an additional 2500sqm of STRATIFIED MEDICINE - ITSMed state-of-the-art laboratories for medical researchers and our partners.” Launched in 2014, ITSMed brings Our research has attracted international researchers Professor Oliver Hanemann, Director of ITSMed including Matthais Futschik, Professor in Bioinformatics, together our world-class research in Edgar Kramer, Professor of Neurodegenerative Diseases, both basic laboratory and translational Professor Ji-Liang Li who joined us from Oxford University clinical science. as Chair in Cancer Immunology, and Professor Syed Hussain who joined us as Chair in Oncology. Our research ITSMed’s effective research collaborations has also resulted in a number of BMJ awards and funding from various bodies such as Innovate UK; MRC, NIHR; and transdisciplinary links between clinical BBSRC, whilst enjoying significant support from charities and non-clinical scientists are underpinned such as Brain Tumour Research. through its integrative ‘bench-to-bedside Through our Biomedical Research Group led by Professor and back’ research strategy. This approach Simon Jackson, we focus on three themes of research: cancer, infection, immunity & inflammation, and clinical to translational medicine which delivers neuroscience, facilitated by cross-cutting expertise in impact and patient benefit is sustained by Diagnostics, Clinical Trials and Public Health research. In these, we have unique combinations of research our Peninsula Clinical Trials Unit. and technologies that are developing critical mass and international recognition, all of which will continue to prosper with the teams operating in the Institute’s brand new physical headquarters, the Derriford Research Facility. 6 7 DERRIFORD RESEARCH FACILITY Derriford Research Facility is an integral Located adjacent to the main Faculty building and neighbouring University Hospitals Plymouth NHS Trust part of the University’s £25 million (Derriford Hospital), it places additional world-class research investment to accelerate the translation of laboratories next door to a major teaching hospital thereby medical and dental research into patient encouraging cross-organisation collaboration. It reflects our role as a research-led University, with a major commitment to care and improved outcomes for people healthcare education. “The physical proximity of living with devastating conditions. Critically It further underpins our drive to transform the medical Derriford Research Facility to the it provides space: space to grow strong research landscape of the region. It will enrich effective hospital provides an even great and resilient teams of biomedical and collaborations with Derriford Hospital, medical and pharmaceutical companies, and is co-located with the boost to collaborative working clinical researchers to work collaboratively Peninsula Clinical Trials Unit, NIHR Peninsula Clinical and advancing clinically relevant and produce significant opportunities to Research Network on Plymouth Science Park. research in the laboratory. This expedite therapeutic treatments. Investment attracts and retains talent; providing researchers with cutting-edge equipment and the space to grow will significantly help to attract teams - including the best PhD students. This in turn further clinical academics at all supports the securing of high value grants and draws in commercial partners. We believe the impact will extend to levels, and research funding to Derriford Hospital, as leading consultants become aware help us achieve our ambitions that Plymouth is a first choice destination for a research- for growing biomedical research, rich career. alongside translational and health services research in Plymouth and surrounding areas.” Professor Adrian Taylor, Associate Dean of Research, Faculty of Medicine and Dentistry 8 9 We are investigating the mechanisms Introducing some key areas within our research environment… that initiate cancers and what makes Our internationally recognised work with low-grade brain tumours meant we were chosen them spread. We are working to to be a Brain Tumour Research Centre of Excellence. Led by Professor Oliver Hanemann it is currently one of only four centres in the UK to be partnered with the Brain Tumour discover approaches for early diagnosis, Research charity. Drs Claudia Barros and Xinzhong Li along with Professors David treatment and prevention in key areas of Parkinson and Ji-Liang Li all currently have funded projects in brain tumour research. cancer research such as brain tumours, Professor Simon Rule has been awarded significant funding by Cancer Research UK leukaemia, lymphomas and oral cancer. to lead a national research study (ENRICH) to compare the efficacy and side effects of using a BTK (Bruton’s Tyrosine Kinase) inhibitor in a trial against standard chemotherapy Our development and success takes in patients with mantle cell lymphoma, a trial which is showing early success with many forms. participating patients in remission. Professor Syed Hussain’s major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up a large number of clinical trials from early phase to late phase studies during his career thus CANCER providing early access to novel drugs for patients. An important focus on the development of new therapies lies at the interface between two of our research areas, cancer and immunology. Professor Ji-Liang-Li who joined us from Oxford University, is investigating the microenvironment of tumours and translational ‘Cancer is a leading cause of death and morbidity cancer medicine aimed at developing new therapeutic targets or biomarkers. His work also investigates the use of immunotherapy in new ways to tackle cancer. worldwide, and with an ageing population and Dental research in oral cancer is led by Dr Bing Hu, focussing on early markers of cancer lifestyle trends its incidence is likely to continue to initiation and biomarkers for metastasis – the spread of cancer. Dr Amiya Patra, Vandervell Senior Research Fellow in Cancer immunity, is exploring rise. Cancer is therefore an important core theme of the role of the immunity transcription factor NFAT (nuclear factor of activated T cells) in leukaemia. NFAT is important in immune response. A better understanding of the our biomedical research’. molecular mechanisms of carcinogenesis – the initiation of cancer formation – allows direct translation into new therapies evaluated in clinical trials. Professor Simon Jackson, Lead, Biomedical Research, ITSMed 10 11 “Moving the University scientists into BLOOD CANCER Derriford Research Facility next to the Professor Simon Rule hospital is key to successful collaboration The aim of our work is to end up with There are more than 100 variants of the Simon Rule, Professor in Haematology at the Faculty of Medicine and Dentistry, and a bio-marker that will tell us how to treat Consultant Haematologist at Derriford Hospital, is one of the world’s leading experts disease